Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

INTRODUCTION: Combination use of onabotulinumtoxinA and calcitonin gene–related peptide (CGRP) monoclonal antibodies (mAbs) has the potential to be more effective than either therapy alone for migraine prevention. METHODS: This retrospective, longitudinal chart review included adults with chronic mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumenfeld, Andrew M., Frishberg, Benjamin M., Schim, Jack D., Iannone, Ashley, Schneider, Gary, Yedigarova, Larisa, Manack Adams, Aubrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586140/
https://www.ncbi.nlm.nih.gov/pubmed/33880725
http://dx.doi.org/10.1007/s40122-021-00264-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586140/
https://www.ncbi.nlm.nih.gov/pubmed/33880725
http://dx.doi.org/10.1007/s40122-021-00264-x

Ejemplares similares